Auris Medical (EARS) Issued Alert Under $1.00

Alerts
Share


share this story above

(NEW YORK) – Ludlow Research has issued an alert on Auris Medical Holding (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care, with an attractive technical analysis below $1.00 per share.

Alert Summary

Sponsor: AppSwarm (OTC:SWRM)

EARS recent run from around $0.30 to a high of $2.00 in just the month of October had pushed the stock into highly over bought territory, with an RSI approaching 90. In addition, EARS had found resistance at its 200-day moving average during this run, which is now around $1.50 per share.

More important, EARS had formed a “gap” in its daily trading chart between $1.00 to $1.25, which historically needs to be ‘refilled’ before most stocks can continue any next leg upwards.

Based on these indicators EARS was obviously positioned for a pullback after such a strong run. But with the RSI pulling back, and price now refilling the gap in daily chart, Ludlow Research feels anything below $1.00 to be a much more attractive trading opportunity for anyone looking to take an entry position in this stock.

Download EARS alert here https://ludlowresearch.com/reports

REGISTER FOR UPDATES

To receive updates on this company report, or on new exclusive investment opportunities, please register to Ludlow Research Investor Mailing list at https://ludlowresearch.com/investors

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1. In addition Auris Medical has two Phase 3 programs under development: AM-111 for sudden sensorineural hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Capital Market under the symbol “EARS.”

 


Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated three thousand five hundred dollars from AppSwarm for ongoing media advisory services, and holds a business relationship with parent company of WSNC, and thus should be considered a possible conflict of interest when reviewing this report and information. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. As of date of this alert, WSNC, or any of its affiliates, held no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.